164 related articles for article (PubMed ID: 29927230)
21. Increased risk of hepatitis B virus reactivation in systemic lupus erythematosus patients receiving immunosuppressants: a retrospective cohort study.
Lin WT; Chen YM; Chen DY; Lan JL; Chang CS; Yeh HZ; Yang SS
Lupus; 2018 Jan; 27(1):66-75. PubMed ID: 28534427
[TBL] [Abstract][Full Text] [Related]
22. Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression.
Salpini R; Colagrossi L; Bellocchi MC; Surdo M; Becker C; Alteri C; Aragri M; Ricciardi A; Armenia D; Pollicita M; Di Santo F; Carioti L; Louzoun Y; Mastroianni CM; Lichtner M; Paoloni M; Esposito M; D'Amore C; Marrone A; Marignani M; Sarrecchia C; Sarmati L; Andreoni M; Angelico M; Verheyen J; Perno CF; Svicher V
Hepatology; 2015 Mar; 61(3):823-33. PubMed ID: 25418031
[TBL] [Abstract][Full Text] [Related]
23. Twenty-four year single-center experience of hepatitis B virus infection in heart transplantation.
Chen YC; Chuang MK; Chou NK; Chi NH; Wu IH; Chen YS; Yu HY; Huang SC; Wang CH; Tsao CI; Ko WJ; Wang SS
Transplant Proc; 2012 May; 44(4):910-2. PubMed ID: 22564582
[TBL] [Abstract][Full Text] [Related]
24. Hepatitis B virus infection and liver function in patients with systemic lupus erythematosus.
Bonafede RP; van Staden M; Klemp P
J Rheumatol; 1986 Dec; 13(6):1050-2. PubMed ID: 3560091
[TBL] [Abstract][Full Text] [Related]
25. Effect of immunosuppressive therapy on patients with inflammatory bowel diseases and hepatitis B or C virus infection.
Morisco F; Castiglione F; Rispo A; Stroffolini T; Sansone S; Vitale R; Guarino M; Biancone L; Caruso A; D'Inca R; Marmo R; Orlando A; Riegler G; Donnarumma L; Camera S; Zorzi F; Renna S; Bove V; Tontini G; Vecchi M; Caporaso N
J Viral Hepat; 2013 Mar; 20(3):200-8. PubMed ID: 23383659
[TBL] [Abstract][Full Text] [Related]
26. Reactivation of hepatitis B virus in HBsAg-negative patients with hepatocellular carcinoma.
Jang JW; Kim YW; Lee SW; Kwon JH; Nam SW; Bae SH; Choi JY; Yoon SK; Chung KW
PLoS One; 2015; 10(3):e0122041. PubMed ID: 25894607
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.
Papadopoulos N; Deutsch M; Manolakopoulos S; Bitsi C; Michalakeas H; Poulakidas H; Tsironi E; Giannouli S; Papatheodoridis GV; Koskinas J; Pectasides D
Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):56-60. PubMed ID: 27669175
[TBL] [Abstract][Full Text] [Related]
28. Current antiviral practice and course of Hepatitis B virus infection in inflammatory arthritis: a multicentric observational study (A + HBV study).
Kalyoncu U; Emmungil H; Onat AM; Yılmaz S; Kaşifoglu T; Akar S; İnanç N; Yıldız F; Küçükşahin O; Karadağ Ö; Mercan R; Bes C; Yazısız V; Yılmazer B; Özmen M; Erten Ş; Şenel S; Yazıcı A; Taşçılar K; Kalfa M; Kiraz S; Kısacık B; Pehlivan Y; Kılıç L; Şimşek İ; Çefle A; Akkoç N; Direskeneli H; Erken E; Turgay M; Öztürk MA; Soy M; Aksu K; Dinç A; Ertenli İ
Eur J Rheumatol; 2015 Dec; 2(4):149-154. PubMed ID: 27708953
[TBL] [Abstract][Full Text] [Related]
29. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.
Kim SJ; Hsu C; Song YQ; Tay K; Hong XN; Cao J; Kim JS; Eom HS; Lee JH; Zhu J; Chang KM; Reksodiputro AH; Tan D; Goh YT; Lee J; Intragumtornchai T; Chng WJ; Cheng AL; Lim ST; Suh C; Kwong YL; Kim WS
Eur J Cancer; 2013 Nov; 49(16):3486-96. PubMed ID: 23910494
[TBL] [Abstract][Full Text] [Related]
30. Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study.
Varisco V; Viganò M; Batticciotto A; Lampertico P; Marchesoni A; Gibertini P; Pellerito R; Rovera G; Caporali R; Todoerti M; Covelli M; Notarnicola A; Atzeni F; Sarzi-Puttini P
J Rheumatol; 2016 May; 43(5):869-74. PubMed ID: 26879359
[TBL] [Abstract][Full Text] [Related]
31. Low prevalence of hepatitis B virus infection in patients with autoimmune diseases in a Chinese patient population.
Sui M; Wu R; Hu X; Zhang H; Jiang J; Yang Y; Niu J
J Viral Hepat; 2014 Dec; 21(12):925-9. PubMed ID: 25143225
[TBL] [Abstract][Full Text] [Related]
32. Clinical characteristics and molecular analysis of hepatitis B virus reactivation in hepatitis B surface antigen-negative patients during or after immunosuppressive or cytotoxic chemotherapy.
Hayashi K; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Tachi Y; Ishikawa T; Katano Y; Yoshioka K; Toyoda H; Kumada T; Goto H; Hirooka Y
J Gastroenterol; 2016 Nov; 51(11):1081-1089. PubMed ID: 26943169
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy.
Koo YX; Tan DS; Tan IB; Tao M; Chow WC; Lim ST
Cancer; 2010 Jan; 116(1):115-21. PubMed ID: 19899164
[TBL] [Abstract][Full Text] [Related]
34. Overt and occult hepatitis B virus infection in adult Sudanese HIV patients.
Mudawi H; Hussein W; Mukhtar M; Yousif M; Nemeri O; Glebe D; Kramvis A
Int J Infect Dis; 2014 Dec; 29():65-70. PubMed ID: 25449238
[TBL] [Abstract][Full Text] [Related]
35. [Investigation of the risk of hepatitis B virus reactivation in arthritis patients undergoing anti-tumour necrosis factor alpha therapy].
Jin D; Tie N; Liu J; Zhao L; Hao D; Zhao Y
Zhonghua Nei Ke Za Zhi; 2015 Apr; 54(4):313-6. PubMed ID: 26268059
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs.
Lee YH; Bae SC; Song GG
Int J Rheum Dis; 2013 Oct; 16(5):527-31. PubMed ID: 24164839
[TBL] [Abstract][Full Text] [Related]
37. The difficulties of managing severe hepatitis B virus reactivation.
Roche B; Samuel D
Liver Int; 2011 Jan; 31 Suppl 1():104-10. PubMed ID: 21205146
[TBL] [Abstract][Full Text] [Related]
38. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.
Law MF; Ho R; Cheung CK; Tam LH; Ma K; So KC; Ip B; So J; Lai J; Ng J; Tam TH
World J Gastroenterol; 2016 Jul; 22(28):6484-500. PubMed ID: 27605883
[TBL] [Abstract][Full Text] [Related]
39. Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice.
Loggi E; Gitto S; Galli S; Minichiello M; Conti F; Grandini E; Scuteri A; Vitale G; Di Donato R; Cursaro C; Furlini G; Andreone P
J Clin Virol; 2017 Aug; 93():66-70. PubMed ID: 28654775
[TBL] [Abstract][Full Text] [Related]
40. Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration.
Hunt CM; Beste LA; Lowy E; Suzuki A; Moylan CA; Tillmann HL; Ioannou GN; Lim JK; Kelley MJ; Provenzale D
World J Gastroenterol; 2016 May; 22(19):4732-40. PubMed ID: 27217704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
